Cargando…
Interference Assessment of Various Endogenous and Exogenous Substances on the Performance of the Eversense Long-Term Implantable Continuous Glucose Monitoring System
Background: A variety of prescriptions and over-the-counter medications interfere with transcutaneous continuous glucose monitoring (CGM) sensors. This study characterized the interference profile of the Eversense(®) CGM System (Senseonics, Inc., Germantown, MD), which has a different mechanism of g...
Autores principales: | Lorenz, Carrie, Sandoval, Wendolyn, Mortellaro, Mark |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Mary Ann Liebert, Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5963543/ https://www.ncbi.nlm.nih.gov/pubmed/29600877 http://dx.doi.org/10.1089/dia.2018.0028 |
Ejemplares similares
-
Clinical Practice Recommendations on the Routine Use of Eversense, the First Long-Term Implantable Continuous Glucose Monitoring System
por: Deiss, Dorothee, et al.
Publicado: (2019) -
SAT-644 A Case of the Use of the Eversense Continuous Glucose Monitor with Repeated Same-Pocket Insertion
por: Lee, Warren, et al.
Publicado: (2020) -
Evaluation of Accuracy and Safety of the Next-Generation Up to 180-Day Long-Term Implantable Eversense Continuous Glucose Monitoring System: The PROMISE Study
por: Garg, Satish K., et al.
Publicado: (2022) -
SAT-638 An Academic Center Experience with the Eversense Continuous Glucose Monitoring System and Assessment of Intrapatient Variability with Repeated Same-Pocket Insertion
por: Lee, Warren, et al.
Publicado: (2020) -
Performance of the Eversense versus the Free Style Libre Flash glucose monitor during exercise and normal daily activities in subjects with type 1 diabetes mellitus
por: Fokkert, Marion, et al.
Publicado: (2020)